- Home
- TYL vs RPRX Comparison
TYL vs RPRX Comparison
Compare TYL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYL | RPRX |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 16.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TYL | RPRX |
|---|---|---|
| Price | $461.98 | $39.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $652.82 | $45.75 |
| AVG Volume (30 Days) | 441.2K | ★ 4.2M |
| Earning Date | 02-11-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 2.27% |
| EPS Growth | ★ 31.32 | N/A |
| EPS | ★ 7.19 | 1.75 |
| Revenue | $2,298,292,000.00 | ★ $2,349,844,000.00 |
| Revenue This Year | $10.91 | $37.66 |
| Revenue Next Year | $8.81 | $2.34 |
| P/E Ratio | $64.66 | ★ $22.18 |
| Revenue Growth | ★ 10.62 | 3.70 |
| 52 Week Low | $445.64 | $24.46 |
| 52 Week High | $661.31 | $41.24 |
Technical Indicators
Market Signals| Indicator | TYL | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 57.44 |
| Support Level | $447.35 | $38.20 |
| Resistance Level | $469.97 | $38.90 |
| Average True Range (ATR) | 9.74 | 0.75 |
| MACD | 1.95 | -0.02 |
| Stochastic Oscillator | 67.09 | 78.54 |
Price Performance
Historical ComparisonAbout TYL Tyler Technologies Inc.
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.